Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Nearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype. However, intrinsic or acquired endocrine resistance can occur during the endocrine treatment. Based on in...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Le-Sang, Jin, Xiao-Yan, Wang, Xu-Meng, Tou, Lai-Zhen, Huang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213629/
https://www.ncbi.nlm.nih.gov/pubmed/32265426
http://dx.doi.org/10.1097/CM9.0000000000000745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213629/
https://www.ncbi.nlm.nih.gov/pubmed/32265426
http://dx.doi.org/10.1097/CM9.0000000000000745

Ejemplares similares